DBV Technologies at guggenheim healthcare conference: launch plan nears

At the 3rd Annual Guggenheim Healthcare Innovation Conference on November 9, 2026, DBV Technologies announced its near completion of preparations for the U.S. launch of Viaskin Peanut, an innovative patch-based treatment for peanut allergy in young children. The company highlighted robust clinical data and a clear commercial strategy, but also noted a warning letter from its contract manufacturer, Fareva Amboise, and a need to secure financing for the upcoming approval and launch.

Viaskin Peanut is currently under FDA review following a Breakthrough Therapy Designation application submitted on September 28 for children aged 4 to 7. The pivotal study demonstrated 47% efficacy with active treatment versus 14% on placebo at one year, with no new safety concerns identified so far. The company expects an FDA action date in late November after a 60-day review period.

A pre-approval inspection is planned to follow the agency's mid-cycle review. DBV's lead product is undergoing an open-label extension to track efficacy in years 2 through 4 of treatment. The company anticipates needing a patient database of at least 600 patients on active treatment for six months as required by the safety database.

DBV plans a specialty launch targeting allergists, with a sales force ranging from 50 to 70 representatives. They intend to reach out directly to consumers through digital channels and advocacy groups, avoiding broad television advertising. The company has already secured logistics and pharmacy distribution partners, and is developing patient services infrastructure to support home-based administration of the patch.

CEO Daniel Tassé emphasized that the company's platform leverages immune properties of the skin through epicutaneous immunotherapy, delivering the Viaskin patch to patients. Viaskin Peanut is designed for children with peanut allergy, affecting approximately 600,000 children in the U.S. in the target age group. The company filed its biologics license application (BLA) on September 28 for the 4- to 7-year-old population and expects the FDA to make a decision in late November.